Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: Role of intracellular tenofovir diphosphate levels and review of the literature

References

• Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Nóvoa S, Solera C, Medrano J, . Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23:689–96.
   PubMed Web of Science ®Google Scholar
• Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses 2009;25:387–94.
   PubMed Web of Science ®Google Scholar
• Pruvost A, Negredo E, Benech H, Theodoro F, Puig J, Grau E, . Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005;49:1907–14.
   PubMed Web of Science ®Google Scholar
• Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, . Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir–ritonavir. Antimicrob Agents Chemother 2009;53: 1937–43.
   PubMed Web of Science ®Google Scholar
• Jansen RS, Rosing H, de Wolf CJ, Beijnen JH. Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:4049–59.
   PubMed Web of Science ®Google Scholar
• Durand-Gasselin L, Da Silva D, Benech H, Pruvost A, Grassi J. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob Agents Chemother 2007;51:2105–11.
   PubMed Web of Science ®Google Scholar
• Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, . Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50:3297–304.
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, . Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008;52: 3144–60.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 2008;47:298–303.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Labarga P, D'Avolio A, Barreiro P, Albalate M, Vispo E, . Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010;24: 1064–6.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Yale K, Shah J, Zhong X, Flaherty JF. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet 2006;45:1115–24.
   PubMed Web of Science ®Google Scholar
• Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS, . Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010;78:1171–7.
   PubMed Web of Science ®Google Scholar
• Barreiro P, Soriano V. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006;57:806–9.
   PubMed Web of Science ®Google Scholar
• Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, . Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens. Antivir Ther 2008;13:231–40.
   Google Scholar
• Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, . The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83:265–72.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, . Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102–8.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, . Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009;48:108–16.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, . Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194:1481–91.
   PubMed Web of Science ®Google Scholar
• Durand-Gasselin L, Van Rompay KK, Vela JE, Henne IN, Lee WA, Rhodes GR, . Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm 2009;6: 1145–51.
   Google Scholar
• Saidenberg-Kermanac'h N, Souabni L, Prendki V, Prie D, Boissier M-C, . Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine 2010; [Epub ahead of print].
   Google Scholar